Bristol's Poker Game: Doubling Down On Research

Medarex acquisition has interesting strategic parallels with the earlier Amgen/Abgenix deal, and demonstrates once again Bristol's distinctive approach of doubling down on research rather than protecting itself through diversification toward slower growth businesses.